骨髓增生异常综合征的遗传学研究进展

岳青芳; 刘新月

骨髓增生异常综合征的遗传学研究进展

岳青芳,
刘新月^,

- 华中科技大学附属协和医院血液病研究所(武汉, 430022)

详细信息

通讯作者: 刘新月,E-mail:lxy87306548@sina.com

中图分类号: R733.7

收稿日期: 2013-06-20

Corresponding author: , E-mail: lxy87306548@sina.com

Received Date: 20 June 2013

摘要

- 骨髓增生异常综合征 /
- 遗传学研究 /
- 进展

HTML全文

参考文献(26)

[1]	COREY S J,MINDEN M D,BARBER D L,et al.Myelodysplastic syndromes:the complexity of stem-cell diseases[J].Nat Rev Cancer,2007,7:118-129.
[2]	BEJAR R,LEVINE R,EBERT B L.Unraveling the molecular pathophysiology of myelodysplastic syndromes[J].J Clin Oncol,2011,29:504-515.
[3]	KAWANKAR N,VUNDINTI B R.Cytogenetic abnormalities in myelodysplastic syndrome:an overview[J].Hematology,2011,16:131-138.
[4]	LI L,LIU XP,NIE L,et al.Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients[J].Leuk Res,2009,33:1194-1198.
[5]	POZDNYAKOVA O,MIRON P M,TANG G,et al.Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes[J].Cancer,2008,113:3331-3340.
[6]	XIAO Y,WEI J,CHEN Y,et al.Trisomy 8 is the most frequent cytogenetic abnormality in de novo myelodysplastic syndrome in China[J].Onkologie,2012,35:100-106.
[7]	MALCOVATI L,NIMER S D.Myelodysplastic syndromes:diagnosis and staging[J].Cancer Control,2008,15(Suppl):4-13.
[8]	SCHANZ J,STEIDL C,FONATSCH C,et al.Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system[J].J Clin Oncol,2011,29:1963-1970.
[9]	BRECCIA M,SALAROLI A,LOGLISCI G,et al.Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine[J].Ann Hematol,2013,92:411-412.
[10]	SKONIECZKA K,DUSZENKO E,WYROWINSKA E,et al.Usefulness of classic cytogenetic testing compared to fluorescence in situ hybridization in genetic diagnosis of 58 patients with myelodysplastic syndromes[J].Pol Arch Med Wewn,2009,119:366-372.
[11]	THIEL A,BEIER M,INGENHAG D,et al.Comprehensive array CGH of normal karyotype myelodysplastic syndromes reveals hidden recurrent and individual genomic copy number alterations with prognostic relevance[J].Leukemia,2011,25:387-399.
[12]	GONDEK L P,TIU R,O'KEEFE C L,et al.Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS,MDS/MPD,and MDS-derived AML[J].Blood,2008,111:1534-1542.
[13]	STARCZYNOWSKI D T,VERCAUTEREN S,TELENIUS A,et al.High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival[J].Blood,2008,112:3412-3424.
[14]	TEFFERI A,VARDIMAN J W.Myelodysplastic Syndromes[J].N Engl J Med,2009,361:1872-1885.
[15]	JIANG Y,DUNBAR A,GONDEK L P,et al.Aberrant DNA methylation is a dominant mechanism in MDS progression to AML[J].Blood,2009,113:1315-1325.
[16]	DELHOMMEAU F,DUPONT S,DELLA VALLE V,et al.Mutation in TET2 in myeloid cancers[J].N Engl J Med,2009,360:2289-2301.
[17]	KOSMIDER O,GELSI-BOYER V,CHEOK M,et al.TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)[J].Blood,2009,114:3285-3291.
[18]	ITZYKSON R,KOSMIDER O,CLUZEAU T,et al.Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias[J].Leukemia,2011,25:1147-1152.
[19]	THOL F,FRIESEN I,DAMM F,et al.Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes[J].J Clin Oncol,2011,29:2499-2506.
[20]	NIKOLOSKI G,LANGEMEIJER S M,KUIPER R P,et al.Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes[J].Nat Genet,2010,42:665-667.
[21]	MAKISHIMA H,JANKOWSKA A M,TIU RV,et al.Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies[J].Leukemia,2010,24:1799-1804.
[22]	WALTER M J,DING L,SHEN D,et al.Recurrent DNMT3A mutations in patients with myelodysplastic syndromes[J].Leukemia,2011,25:1153-1158.
[23]	PATNAIK M M,HANSON C A,HODNEFIELD J M,et al.Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes[J].Leukemia,2012,26:101-105.
[24]	YOSHIDA K,SANADA M,SHIRAISHI Y,et al.Frequent pathway mutations of splicing machinery in myelodysplasia[J].Nature,2011,478:64-69.
[25]	MAKISHIMA H,VISCONTE V,SAKAGUCHI H,et al.Mutations in the spliceosome machinery,a novel and ubiquitous pathway in leukemogenesis[J].Blood,2012,119:3203-3210.
[26]	KAO H W,SANADA M,LIANG D C,et al.A high occurrence of acquisition and/or expansion of C-CBL mutant clones in the progression of high-risk myelodysplastic syndrome to acute myeloid leukemia[J].Neoplasia,2011,13:1035-1042.